Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms

  title={Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms},
  author={François Curtin and Patricia Berney and C. Kaufmann},
  journal={Journal of Psychopharmacology},
  pages={271 - 272}
A case of moclobemide discontinuation syndrome who predominantly presented with influenza-like symptoms is presented. Sertraline treatment did not modify the symptoms, which may suggest different mechanisms with regard to different antidepressant drug discontinuation syndromes. Implications for clinical care are reviewed. 
A case of discontinuation syndrome following the discontinuation of low-dose mirtazapine therapy in malignant lymphoma
The case of a 69-year-old woman with malignant lymphoma who suffered from major depressive disorder and a low dose of mirtazapine (15 mg/day) brought about dramatic improvement in her mental status, but after discontinuation, anxiety, restlessness, irritability, nausea, insomnia, imbalance and sensory disturbances occurred. Expand
Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
The results show that clinicians should be aware that vortioxetine withdrawal is associated with the possibility of discontinuation symptoms (DS) and that patients with depressive disorders who discontinued former vortoxetine treatment ought to be aware of this possibility. Expand
Antidepressant discontinuation syndrome.
Before antidepressants are prescribed, patient education should include warnings about the potential problems associated with abrupt discontinuation, and a high index of suspicion should be maintained for the emergence of discontinuation symptoms. Expand
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of majorExpand
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.
The Task Force on Antidepressant Medications was established to examine all aspects of therapy with antidepressant drugs and to provide mental health and other professionals with comprehensive and objective information about the different aspects of the use of antidepressants important in clinical practice. Expand
Current Awareness: Pharmacoepidemiology and Drug Safety
  • 2003
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliographyExpand
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
Practical advice is given in terms of dietary restrictions, interactions with other medications, and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. Expand


Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
OBJECTIVE To establish specific criteria by which selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome may be identified. DATA SOURCES MEDLINE and PSYCHLIT databases were searchedExpand
Serotonin reuptake inhibitor withdrawal.
Reports of withdrawal symptoms in a retrospective chart review of 352 patients treated in an outpatient clinic with the nonselective serotonin reuptake inhibitor clomipramine or with one of the selective SSRIs, fluoxetine, fluvoxamine, paroxettine, or sertraline suggest a role has been suggested for serotonin in coordinating sensory and autonomic function with motor activity. Expand
Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder
The data suggest moclobemide is a well tolerated and effective treatment for panic disorder and Evaluation of the tolerability in a long-term study of up to 1 year is still in progress. Expand
Withdrawal Phenomena Associated with Antidepressant and Antipsychotic Agents
The withdrawal of heterocyclic antidepressants and antipsychotic agents can produce nausea, emesis, anorexia, diarrhoea, rhinorrhoea, diaphoresis, myalgias, paraesthesias, anxiety, agitation, restlessness and insomnia and is usually prevented by gradually reducing the total daily dosage of the pertinent drug. Expand
Moclobemide safety: monitoring a newly developed product in the 1990s.
The safety profile of the product after 3 years on world markets is presented, largely unchanged from those observed at 1 and 2 years postlaunch, when the estimated exposed populations were 168,000 and 328,000, respectively. Expand
Antidepressant Discontinuation Syndromes
Discontinuation symptoms have received little systematic study and most of the recommendations made here are based on anecdotal data or expert opinion, so research is needed to provide a firm evidence base for future recommendations. Expand
Pre-clinical pharmacology of moclobemide. A review of published studies.
Moclobemide only slightly potentiates the pressor effect of oral tyramine in freely moving rats, again in contrast to tranylcypromine; it is not anti-cholinergic and is free of hepatotoxicity. Expand
Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Moclobemide administration leads to increased monoamine receptor stimulation, reversal of reserpine induced behavioral effects, selective depression of REM sleep, down regulation of beta-adrenoceptors and increases in plasma prolactin and growth hormone levels which suggest a neuroprotective role. Expand
Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice
Compared in male NMRI mice the simultaneous evolution of blood serotonin (5-HT) concentrations, and 5-HT parameters in the dorsal raphe, caudate nucleus and frontal cortex after clomipramine, fluoxetine and moclobemide treatments is compared to show significantly different effects between central and peripheral indices of 5- HT metabolism according to time and to the antidepressant assessed. Expand
Antidepressant discontinuation syndromes. Clinical relevance, prevention and management
  • Drug Safety
  • 2001